AU2002322923A1 - Oral rinse for treatment or prevention of bacterial and fungal infection - Google Patents

Description

The vehicle body frame puller attachment according to the present invention substantially departs from the conventional concepts and designs of the prior art, and in so doing provides an apparatus primarily developed for the purpose of providing a versatile attachment device having a multiplicity of connection structures for attaching to various points on an vehicle body.

SUMMARY OF THE INVENTION

In view of the foregoing disadvantages inherent in the known types of vehicle body attachments now present in the prior art, the present invention provides a new vehicle body frame puller attachment wherein the same can be utilized for providing a versatile attachment device having a multiplicity of connection structures for attaching to various points on an vehicle body.

The present invention generally comprises a generally triangular main member having three sides with opposite side edges extending along each of the sides. The main member comprises a first side adapted for coupling to a chain to facilitate pulling on the main member using the chain, with a generally round aperture for freely passing a portion of a chain therethrough and a pair of chain slots for positioning a linlc of the chain in one of the chain slots such that an adjacent link in the chain is prevented from passing through the chain slot. A second side has four door hinge (and frame rail) slots with each of the door hinge slots being elongate and having longitudinal axes extending substantially parallel to the side edges. A third side has a plurality of bolt slots for coupling to various bolt patterns used to attach door hinges to different vehicles. Optionally, a pair of brackets is provided for adjustably coupling to the door hinge slots of the second side of the main member and for engaging a respective end of a door hinge on a door post of the vehicle body. Also optionally, a loop may be mounted on the main member for receiving a portion of a chain, with the loop being looped about the main member.

The invention has special versatility for pulling on various locations of the frame rails of a vehicle body. ORAL RINSE FOR TREATMENT OR PREVENTION OF BACTERIAL AND

FUNGAL INFECTION

Field of the Invention

[0001] This invention relates to a mouthwash composition and method for treating or preventing bacterial and fungal infection in the oral cavity, which causes conditions such as bad breath, also referred to as halitosis or oral malodour, periodontal disease and gingival inflammation or bleeding.

Background of the Invention

[0002] Oral malodour (halitosis), or as it is commonly known, bad breath, is a condition that affects between 40% and 50% of the population. It is widely accepted that most individuals afflicted with oral malodour also experience psychosocial problems related to this condition. In addition to breath odour, individuals may have an unpleasant taste, described as bitter, dry, stale, fecal, metallic, hot or pasty, and they associate this taste with the presence of tainted breath, even when the mouth air has no detectable odour.

[0003] It is generally believed that the cause of this condition is due to the presence of anaerobic bacteria, especially gram-negative anaerobic bacteria, within the oral cavity. These bacteria actively degrade the sulfur-containing amino acids, methionine and cysteine, to generate pungent compounds collectively known as volatile sulfur compounds (NSC). Hydrogen sulfide (H-S-H), methyl mercaptan (CH₃-S-H) and dimethyl sulfide (CH₂-S-CH₃) are the principal odorous components generated. These substances, especially methyl mercaptan, have an unpleasant odour, even in very low concentrations, and the exhalation of these volatile sulfur compounds is perceived as bad breath.

[0004] It is also recognized that NSC can produce biologic effects such as altering the epithelial barrier within the oral cavity, resulting in bleeding and inflammation. For example, methyl mercaptan enables the penetration of bacterial toxins into the underlying connective tissue through the increased permeability of the oral mucosa. This volatile sulfur compound can alter enzymatic and immunologic activities, delay wound healing and influence gene activity through the alteration cell shape and cytoskelton pattern (Tonzetich, Bad Breath, A Multidisciplinary Approach. 79 -91, 1996).

[0005] It has been established that systemic conditions, including liver and kidney abnormalities, diabetes, oral cancers, chronic sinusitis and tonsillitis, can also contribute to oral malodour. Periodontal diseases are a cluster of widespread inflammatory conditions that have an association with substantial VSC production. Oral microorganisms, predominantly gram negative anaerobic flora, contribute to the initiation and progression of periodontal diseases as well as substantial oral malodour.

[0006] Various oral rinse preparations are known for treating halitosis. US

Patent 4,525,342 (Weiss et al.; June 25, 1985) discloses a composition comprising a salt water aqueous phase and an oily phase in a double compartment double squirt bottle that allows an emulsion to be generated in the mouth during rinsing. US Patent 5,401,496 (Fitzig et al; March 28, 1995) discloses a preparation comprising a synthetic oil of a caprylic/capric triglyceride mixture. US Patent 5,738,840 (Richter; April 14, 1998) discloses an aqueous composition comprising molecular chlorine dioxide and a metal chlorite salt. US Patent 6,071,500 (Thistle; June 6, 2000) discloses a breath cleansing spray that includes xylitol as a sweetener and calcium hydroxide to raise the pH of the saliva. US Patent 6,132,701 (Perez et al.; October 17, 2000) discloses a method for reducing halitosis that includes generating an aqueous solution of calcium hydroxide for rinsing an oral cavity. In general, known anti-halitosis mouthwashes may not remove the often bitter or pasty taste that causes distress to the individual, suggesting that they leave microorganisms in numbers large enough to produce byproducts that continue to affect the taste perceptions of the individual.

[0007] Metronidazole is used for the treatment of several types of anaerobic infections including periodontal disease. Short-term, systemic use of metronidazole administered orally in humans caused a sustained reduction of anaerobic gram- negative microorganisms, including spirochetes, Bacteroides sp., Fusobacterium sp., and the anaerobic cocci, Peptostreptococcus sp., for weeks to months, with improved periodontal health (/. Clin Periodontol. 8:29-44, 1981). Although it is well absorbed within 1 to 2 hours after ingestion, between 60 to 80% of the drug is excreted. US Patent 4,997,830 (van Winkelhoff et al.; March 5, 1991) discloses a pharmaceutical composition comprising metronidazole and amoxicillin for the treatment of periodontitis.

[0008] However, systemic use of metronidazole can have undesirable side effects such as nausea, headaches and gastrointestinal discomfort. US Patent 4,568,535 (Loesche; February 4, 1986) discloses a slow release film for placement in the oral cavity in a periodontal pocket, the film including metronidazole. However, such a film requires a dental professional to fit it and may be uncomfortable.

[0009] Microfungal infections of the oral cavity are a problem often associated with oral lesions and dryness. Many individuals who complain about bad breath and bad taste have substantial numbers of yeast organisms, in addition to the gram- negative anaerobic bacteria. Gingival bleeding is often also present in these individuals. The Candida species are aerobic yeasts that can also grow anaerobically. C. albicans is the species most often responsible for infections in the oral cavity and may cause a variety of disorders including gingival bleeding and denture stomatitis. Oral candidiasis is an extremely virulent and uncomfortable condition, especially prevalent in the aged and those with chronic debilitating ailments.

[0010] The establishment of a mycotic infection in the oral cavity presents a serious health problem to the individual. Thus, it is desirable to treat and contain this infection through both mechanical methods such as proper oral cleansing as well as chemical therapy in the form of antifungal drugs. However, systemic administration of antimycotics, in doses high enough to control oral infections, can induce undesirable side effects.

[0011] Nystatin is a polyene antifungal, antibiotic complex that is used for the treatment of fungal infections. Nystatin binds to the covering membrane of fungi altering the cell membrane thus leading to cell death. It is both fungicidal and fungistatic against a variety of yeasts and fungi. Nystatin is applied topically in most cases.

[0012] Canadian Patent Application 2,008,772 (Friedman; published July 31,

1990) discloses a sustained-release oral antifungal varnish, that includes nystatin in a sustained-release polymer, and states that mouth rinses that include antifungal drugs do not maintain the drugs at efficacious levels in the oral cavity. US Patent 4,725,440 (Ridgway et al.; February 16, 1988) discloses an antifungal pastille formulation for treating oral candidiasis by a relatively slow release of the antimicrobial agent, including nystatin, and indicates that use of nystatin in an oral suspension is not considered an effective way to treat oral candidiasis. PCT publication WO 99/61491 (Kolias et al.; published December 2, 1999) discloses an antimicrobial denture adhesive, for the treatment of denture stomatitis, that includes nystatin as the active ingredient.

[0013] None of the above references relate to use of metronidazole and nystatin together in an oral rinse composition.

Summary of the Invention

[0014] It has not been appreciated until now that a mouthwash-based combination therapy comprising metronidazole and nystatin, as set out below, can alleviate oral conditions such as halitosis, periodontal disease and gingival inflammation or bleeding.

[0015] Therefore, the present invention provides a mouthwash composition for the treatment or prevention of bacterial and fungal infection in the oral cavity, the mouthwash composition comprising an effective amount of metronidazole and nystatin, together with an orally-acceptable carrier, such as water.

[0016] The present invention also provides a method for the treatment or prevention of bacterial and fungal infection in the oral cavity, the method comprising the step of rinsing an oral cavity with a composition comprising an effective amount of metronidazole and nystatin, together with an orally-acceptable carrier, such as water. [0017] The present invention also provides use of an effective amount of metronidazole and nystatin for the manufacture of a product for the treatment or prevention of bacterial and fungal infection in the oral cavity.

[0018] The composition, use and/or method described herein can be used for the treatment or prevention of halitosis, a periodontal disease, or gingival inflammation or bleeding.

[0019] Metronidazole, and hence the composition, use and /or method described herein, can be used to treat bacterial infections, such as those caused by a bacterial pathogen selected from the group consisting of obligate anaerobic gram- negative bacilli such as Bacteroides sp (e.g. B.fragalis), Fusobacterium, Clostridium sp and certain anaerobic protozoal parasites such as Trichomonas, Giardia and Entamoeba. It also has bactericidal activity against the obligate anaerobic cocci isolated from infections in the oral cavity, Peptococcus sp and Peptostreptococcus sp. It is also effective in the treatment of mixed bacteria infections, that is a combination of anaerobes and aerobes.

[0020] In the oral cavity, bacterial infection is typically caused by a bacterial pathogen selected from the group consisting of Bacteroides sp, Fusobacterium sp, Spirochetes, Clostridium sp, Peptococcus sp and Peptostreptococcus sp.

[0021] Nystatin, and hence the composition, use and/or method described herein, can be used to treat fungal infections, including those caused by a Candida fungal pathogen, such as Candida albicans which can be found in oral cavity infections.

[0022] The advantages provided by the present invention include ease of use of a mouth rinse, with none of the side effects found in systemic use of both metronidazole and nystatin, and none of the inconvenience of topical formulations. Also, metronidazole and nystatin appear to act in synergy to produce positive results in patients that had not found relief from halitosis using conventional treatments. Furthermore, the composition of the present invention removes sufficient anaerobes and yeasts that an individual no longer has a perception of a bad taste. [0023] The addition of the nystatin prevents the formation of yeast during the process of removing the anaerobes as well as eliminating yeast in those subjects where it is already present. It was observed that gingival and palatal tissue response is improved with the inclusion of nystatin in the composition, relative to metronidazole alone. Patients also reported a greater decrease in oral dryness with the inclusion of nystatin in the composition relative to metronidazole alone.

[0024] Other aspects and advantages of embodiments of the invention will be readily apparent to a person of ordinarily skilled in the art upon review of the following description.

Detailed Description of the Preferred Embodiments

[0025] The present invention relates to a vehicle that can effectively eliminate oral malodour and reduce the extent of periodontal diseases, especially the inflammatory process. The combination of metronidazole and nystatin in an aqueous suspension, when applied to the oral cavity for no less than 30 seconds several times a day, can decrease anaerobic bacteria and oral yeast within a two week period, with a noticeable difference in breath malodour and tissue status within in 24 to 48 hours.

[0026] In the composition, use and/or method of the invention, nystatin is preferably present at a concentration of about 20,000 to about 600,000 LU. per ml (based on 100,000 LU. per gram, this equates to a range of about 200 to about 6000 mg per ml), and is typically present at a concentration of about 100,000 LU. per ml. Metronidazole is preferably present at a concentration of about 5 to about 200 mg per ml, more preferably between about 20 to about 50 mg per ml. One embodiment is contemplated in which, when nystatin is present at 100,000 LU. per gram, metronidazole is not present at 50 mg per ml. Another embodiment is contemplated in which, when metronidazole is present at 50 mg per ml, nystatin is not present at 100,000 LU. per gram.

[0027] Metronidazole (Apo-Metronidazole, Apotex Research Inc.) was prepared by grinding tablets into a powder form and water is added to make a paste. The paste was added to a suitable quantity of nystatin, which was obtained as an aqueous solution from Alimed or PMS PharmaScience (Nilstat™). Metronidazole does not dissolve in water but forms a paste that, when added to nystatin, forms a suspension. A typical 190 ml batch of oral rinse comprises 40 ml of metronidazole paste added to 150 ml nystatin solution. The mouth rinse has a slightly sticky consistency that provides effective contact with the tissues.

[0028] The composition, use and /or method of the invention can also include additives such as a corticosteroid, for example hydrocortizone at about 0.5 to about 2% per ml, which acts to promote healing of oral tissues. Pain relief agents, such as lidocaine, can also be added. In addition, a self-sterilizing agent, a flavouring agent, a colouring agent, and the like, may optionally be included as appropriate.

[0029] Preferably, a volume of about 3 to about 5 ml of the above formulation is used three times a day. If necessary, the volume and rinse frequency can be varied as appropriate. A treatment period of 14 days was found to be suitable, but this period can be varied as necessary.

Procedures

[0030] Oral hygiene procedures, including tongue cleaning, were generally performed prior to using a formulation, which was used by all adult subjects, the formulation comprising metronidazole at 50 mg per ml (25 mg per ml for children) and nystatin at 100,000 LU. per ml.

[0031] The mouth was cleared of debris and cleansing materials by rinsing well with water. A dose of about 3 to 5 ml of the metronidazole /nystatin suspension was taken 3 times a day for a period of 14 days. The suspension was swished and gargled in the mouth for a period of 30 seconds and then expectorated. There was no rinsing or eating for at least 30 minutes after the procedure, to let the medication take affect. Normal flossing was carried out after the morning and evening rinse. With more persistent cases of interproximal bleeding or odour, after a 14 day treatment course, floss was dipped into a capful of the above-noted formulation and wet flossing carried out and the results subsequently monitored. Clinical Results

[0032] , The following tables are clinical data showing the efficacy of the nystatin-metronidazole rinse. Fifty four subjects received treatment with this medication.

[0033] Twelve of the subjects were treated with 0.2% chlorhexidine prior and evaluated for response prior to treatment with nystatin-metronidazole. These subjects used chlorhexidine twice a day rinsing for 60 seconds each time for a period of 14 days. Chlorhexidine was brushed into the tongue and carried into the gingival sulcus using an appropriate vehicle, such as floss, superfloss or proxabrush, soaked in the chlorhexidine. After the two weeks, subjects were evaluated for changes. These subjects still had some oral odours and in some cases had slightly more than the original measurements.

[0034] Subjects were instructed to refrain from food, drink and oral hygiene for two hours prior to each appointment. All subjects were instructed to refrain from garlic, onions, alcohol, spices, mouthwashes, and scented cosmetics for at least 24 hours.

[0035] The extent of the malodour for each subject has been established by taking volatile sulfur measurements in concentrations of parts per billion with a Halimeter™, a portable sulfur monitor adapted for oral use by InterScan Corporation, Chatsworth, California. It is relatively accurate instrument for the measurement of hydrogen sulfide but measures methyl mercaptan to about a 50% accuracy and dimethyl sulfide to an even lesser degree. When the predominant odour is methyl mercaptan, there is usually a low reading on the Halimeter when compared to the organoleptic rating.

[0036] Organoleptic ratings of mouth air, nasal air, tongue base, tongue dorsum and floss were established by three trained, experienced judges. Two criteria, bleeding on probing and measurement of periodontal pockets, were used to determine the extent of gingival bleeding and periodontal status. A calibrated probe was used to assess the probing depth of a sulcus or periodontal pocket. The rod- shaped working end of the probe is marked in millimeter units and is similar to a ruler. The probe was inserted into the sulcus or pocket and the depth measured from the junction of the tooth and gum tissue (epithelial attachment) to the top of the gum or gingival margin. Healthy gums or gingiva have pockets that range from 0.5 to 3.0 mm in depth. A depth greater than 3.0 mm is called a periodontal pocket. To measure the depth of the sulcus or pocket, the probe was held lightly and the working end of the instrument placed against the enamel and gently inserted beneath the gum until there was a soft but resilient resistance. The probe was walked around the entire circumference of the tooth and measurements of 4 mm and greater were recorded. There are six areas at which measurements were taken, 3 on the surface next to the cheek and 3 on the surface next to the tongue. These evaluations were performed just before treatment and fourteen days after treatment for all subjects except where stated otherwise.

[0037] Some subjects were evaluated 24 to 48 hours after taking the nystatin- metronidazole rinse because they travelled a significant distance (e.g. South America) and could not stay for the 14 day term. However, they were required to complete the nystatin-metronidazole rinse and report by telephone or email as to further progress.

[0038] Tables 1A, IB and 1C show the pretreatment and post-treatment levels of odours, periodontal involvement and microbiology of subjects who were treated with a commercially available aqueous 0.2% chlorhexidine solution (Perio Works, Vernon, BC). Table ID shows the measurements of these same subjects following treatment with the nystatin-metronidazole formulation detailed above.

[0039] Tables 2A, 2B and 2C show the pretreatment and post-treatment levels of odours, periodontal involvement and microbiology of subjects immediately following measurements on the first appointment, and then following two weeks of treatment with the nystatin-metronidazole formulation detailed above.

Abbreviations used in Tables

[0040] Org.m - organoleptic assessment of mouth air. [0041] Org.tb - organoleptic assessment of the base of the tongue.

[0042] Org.td - organoleptic assessment of tongue dorsum.

[0043] Org.f - organoleptic assessment of floss odours.

[0044] nr - not recorded.

[0045] spiro - Spirochetes

[0046] fuso - Fusobacterium

[0047] gr- bacilli - Gram negative bacilli

[0048] gr- cocci - Gram negative cocci

[0049] gr- coccobacilli - Gram negative coccobacilli

[0050] Organoleptic measurements use the scale 0-5, with the following meanings: 0 - no odour; 1 - slightly perceivable and fleeting odour; 2 - mild but definite; 3 - moderate; 4 - strong; 5 - very strong. The pocket depth (in mm) is stated, followed by the number of pockets in brackets.

Table 1A: VSC and organoleptic assessments of individuals with oral malodour prior to treatment with chlorhexidine.

Patient Sex Age VSC Ore.m Org.tb Org .td Org.f Taste Bleeding Pockets (mn )

AY2596 F 29 53 2 3 1 5 bitter no no

SB2400 M 29 62 3 3 0 2 dry no no

HE2046 M 57 51 4 5 4 5 none no no

KT2016 F 25 82 4 4 4 2 bad no 6 (3)

ZT2557 M 40 36 1 0 1 0 none no 4 (1)

JM2142 F 35 47 2 1 3 0 bitter no no

KN2036 M 39 41 4 nr 2 5 dry no no

CD2416 F 33 79 3 4 2 0 sour no no

EC2010 F 54 93 4 5 3 5 bad no 4 (1)

VC2399 M 37 134 3 3 2 2 none yes no

JA2021 F 47 45 3 4 3 2 none no 4 (1)

TB2425 M 18 39 3 2 0 0 manure no no

Table IB: Microbiology of the tongue and interproximal plaque of individuals in

10 Table 1A, assessed by a commercial laboratory prior to treatment with 0.2% chlorhexidine.

Patient Sex Age spiro fuso gr- bacilli gr- cocci gr- coccobacilli yeast

AY2596 F 29 yes no yes yes yes no

SB2400 M 29 no no yes yes no no

HE2046 M 57 yes yes yes yes no no

KT2016 F 25 yes no yes yes no yes

ZT2557 M 36 yes no yes no no yes

JM2142 F 35 yes yes yes yes no yes

KN2036 M 39 yes yes yes yes no yes

CD2416 F 33 yes no yes yes no no

EC2010 F 54 yes yes yes yes no yes

VC2399 M 37 yes no yes yes yes no

JA2021 F 47 yes yes yes yes no yes

TB2425 M 18 no no yes no no no

Table IC: VSC and organoleptic assessments of individuals from Table 1 A post treatment with a 0.2% chlorhexidine rinse for two weeks.

Patient Sex Age VSC Org.m Org.tb Or Egg-.td Org.f Taste Bleeding Pockets (mm)

AY2596 F 29 42 2 nr 2 0 bitter no no

SB2400 M 29 53 0 3 0 0 none no no

HE2046 M 57 26 4 nr 4 4 none no no

KT2016 F 25 37 0 0 2 2 nr no nr

JM2142 F 35 116 0 nr 2 0 nr no no

KN2036 M 39 43 0 nr 0 5 none no no

CD2416 F 33 112 3 3 2 0 nr no no

EC2010 F 54 149 3 nr 3 3 improved no nr

VC2399 M 37 50 2 3 2 0 none no no

JA2021 F 47 31 3 nr 1 3 none no nr

TB2425 M 18 89 3 nr 3 2 dry no no

Table ID: VSC and organoleptic assessments of individuals from Table 1 A post treatment with the nystatin-metronidazole rinse following the two week 0.2% chlorhexidine rinsing. Patient Sex Age VSC Org.m Org.tb Org td Org.f Taste Bleeding Pockets (mm)

AY2596 F 29 52 0 nr 0 0 none no no

SB2400 M 29 31 0 0 0 0 none no no

HE2046 M 57 34 0 nr 0 0 none no no

KT2016 F 25 30 0 0 0 0 none no nr

ZT2557 M 36 30 0 0 0 0 none no nr

JM2142 F 35 55 0 0 0 0 nr no no

KN2036 M 39 41 0 nr 0 0 none no no

CD2416 F 33 39 2¹ nr 0 0 none no no

EC2010 F 54 39 0 nr 0 0 none no nr

11 VC2399 M 37 36 2¹ nr 0 0 none no no

JA2021 F 47 27 0 0 0 0 none no nr

TB2425 M 18 44 0 0 0 0 none no no

¹ Garlic odour from diet.

Table 2A: VSC and organoleptic assessments of individuals with oral malodour, prior to treatment with the nystatin-metronidazole formulation.

Patient Sex Aεe VSC Org.m Ore.tb Oretd Ore.f Taste Bleedine Pockets (mm)

CW2714 F 24 362 5 5 5 4 dry no no

FA2221 M 45 127 5 4 4 3 metallic no 4

RN1464 F 52 59 5 4 4 0 nr no no

DM2413 M 44 61 3 3 3 0 bitter no 4 (1)

MG2105 F 58 67 5 2 5 5 sour no no

GK2809 F 53 78 2 2 2 3 thick yes 5 (6)

RL2646 M 35 212 4 4 4 2 metallic no no

SL2510 F 52 49 4 5 4 3 none nr nr

JP2600 M 24 64 5 5 5 2 acrid yes no

EP2799 M 50 198 3 4 3 2 none no no

AR2620 F 34 115 3 4 1 3 metallic yes 4 (many)

GW2158 F 36 81 4 3 4 3 strong no no

GB2808 F 21 283 4 4 2 0 sour yes 4 (6)

MC2648 M 35 65 5 5 3 2 metallic no 5 (2)

LP2546 F 52 84 3 3 1 1 pasty no 4 (2)

GK2712 F 68 394 4 5 5 5 bitter yes no

SB2679 F 33 70 4 4 1 4 foul no no

CG2304 F 54 135 3 4 3 5 foul no no

RJ2386 M 39 55 1 4 0 2 none yes 4 (2)

CB2564 F 36 , 308 5 5 2 2 bitter no no

MH2009 M 8 55 3 3 2 0 none no no

NG2411 M 50 142 4 5 3 2 acid no 5 (3), 7 (1)

HT2384 M 81 38 3 4 1 5 bad yes 4 (3), 5 (3)

PB2914 M 36 60 1 3 1 1 dry yes 4 (4)

RK2950 F 51 56 2 3 1 2 stale yes 4 (2), 5 (4)

BB2747 F 43 62 4 nr 0 5 burning yes 5 (4), 4 (2)

FB2429 F 41 144 4 4 3 5 stale yes no

MA2826 F 55 30 0 3 0 3 metallic yes 5 (2), 4 (1)

PE2195 M 62 129 4 3 3 0 none no 5 (1)

SDR2579 M 45 568 5 5 3 4 acid no no

EE2314 F 50 210 5 4 4 5 metallic yes many

CF2689 M 39 900 5 5 5 3 none yes many

MS2784 F 27 208 4 5 4 0 bitter yes 4 (2)

PS2762 M 31 101 4 4 3 2 none yes 4 (6), 5 (4)

DL2390 F 25 66 0 4 3 2 metallic no 4 (8)

SN2835 F 27 08 4 5 3 2 metallic yes no

LM2862 F 26 139 3 4 3 0 bitter yes no

RM2452 M 44 85 4 2 3 1 metallic yes 5 (2)

MF2665 M 44 75 4 4 2 3 metallic no no

12 BF2812 M 32 145 3 4 3 0 sulfuric yes 5 (4), 4 (2)

JF2887 M 41 243 4 3 3 0 none no 4 (3)

MG2890 M 38 260 4 4 3 3 tinny yes no

EG2701 M 26 220 3 4 2 2 sulfuric no no

LG2367 F 26 86 4 4 4 3 stale yes 5 (2)

AG2558 F 46 66 3 3 1 5 none yes no

MG2793 F 34 152 3 4 3 3 bitter yes no

MG2709 F 25 198 5 4 5 5 stale yes 4 (1), 5 (5)

AG2338 M 40 223 5 5 4 5 bitter no 4 (2), 5 (2)

MH2361 M 43 82 5 5 5 3 stale no 4 (3)

SM2954 M 27 110 3 3 3 3 dry yes no

GL2952 F 3781 3 3 3 3 2 bitter no no

Table 2B VSC and oi ^•ganoleptic assessments of individuals with oral ma lodour prior to treatment with the nystatin- -metronidazole formulation.

Patient Sex Age spiro fuso gr- bacilli g r- cocci gr- coccobacilli veast

CW2714 F 24 no no yes no no no

FA2221 M 45 yes yes yes yes yes yes

RN1464 F 52 yes yes yes yes no yes

DM2413 M 44 no no yes yes no no

MG2105 F 58 yes yes yes yes no yes

GK2809 F 53 yes yes yes no no no

RL2646 M 35 yes yes yes yes no yes

SL2510 F 52 yes no yes yes no yes

JP2600 M 24 no no yes yes no yes

EP2799 M 50 yes yes yes no no no

AR2620 F 34 yes no yes yes no no

GW2158 F 36 yes yes yes yes no yes

GB2808 F 21 no yes yes no yes no

MC2648 M 35 yes no yes yes no yes

LP2546 F 52 no no yes yes no yes

GK2712 F 68 yes no yes yes yes no

SB2679 F 33 yes no yes yes no no

CG2304 F 54 yes no yes yes no no

RJ2386 M 39 yes no yes yes no no

CB2564 F 36 no no yes yes no no

MH2009 M 8 no no yes no yes no

NG2411 M 50 yes no yes yes no no

HT2384 M 81 yes no yes yes no no

PB2914 M 36 no yes yes no yes yes

RK2950 F 51 no yes yes no yes no

BB2747 F 43 yes no yes yes no no

FB2429 F 41 yes no yes yes no no

MA2826 F 55 yes yes yes no no no

PE2195 M 62 yes yes yes yes no yes

SDR2579 M 45 yes no yes yes no yes

EE2314 F 50 yes yes yes yes yes yes

CF2689 M 39 yes no yes yes no no

MS2784 F 27 no yes yes no no no

13 PS2762 M 31 no no yes yes no no

DL2390 F 25 no no yes yes yes no

SN2835 F 27 yes yes yes no no no

LM2862 F 26 yes yes yes no no no

RM2452 ^■ M 44 yes no yes no yes no

MF2665 M 44 yes no yes yes no yes

BF2812 M 32 no yes yes no no no

JF2887 M 41 yes yes yes no no no

MG2890 M 38 no yes yes no no no

EG2701 M 26 yes no yes no no no

LG2367 F 26 yes yes yes yes no no

AG2558 F 46 no no yes yes no yes

MG2793 F 34 yes yes yes no no yes

MG2709 F 25 yes no yes yes no no

AG2338 M 40 yes no yes no no no

MH2361 M 43 yes no yes no no no

SM2954 M 27 yes yes yes no no no

GL2952 F 37 no yes yes no yes no

Table 2C: VSC and organoleptic assessments of individuals from Table 2A post treatment with the nystatin-metronidazole formulation. Patient Sex Age VSC Org.m Org.tb Org td Org.f Taste Bleeding Pockets (mm)

CW2714 F 24 28 0 0 0 0 none no no

FA2221 M 45 37 0 0 0 0 none no no

RN1464 F 52 40 0 0 0 0 none no no

DM2413 M 44 30 0 nr 0 0 none no no

MG2105 58 34 0 nr 0 0 none no no

GK2809 53 19 0 0 0 0 none improved nr

RL2646 M 35 50 0 0 1 0 none no no

SL2510 F 52 13 0 0 0 4 none improved nr

JP2600 M 24 43 0 0 0 0 none no no

EP2799 M 50 28 0 3 0 0 none no no

AR2620 F 34 38 0 0 0 0 none improved improved

GW2158 36 42 0 0 0 0 none no no

GB2808 21 22 0 1 0 1 none improved improved

MC2648 M 35 55 0 0 0 0 none no nr

LP2546 F 52 42 0 0 0 0 none no nr

GK2712 68 20 0 1 0 3 none improved no

SB2679 33 45 0 0 0 2 none no no

CG2304 54 12 0 0 0 0 none no no

RJ2386 M 39 34 0 0 0 0 yes improved improved

CB2564 F 36 35 0 0 0 0 none no no

MH2009 M 8 25 1 1 0 0 none no no

NG2411¹ M 50 41 0 0 0 4 none improved nr

HT2384 M 81 38 0 0 0 4 none improved improved

PB2914 M 36 50 0 1 1 0 dry no 4 (2)

RK2950 51 10 0 0 0 0 none improved nr

BB2747 43 24 0 0 0 0 none improved nr

FB2429 41 28 0 nr 0 2 none improved no

14 MA2826 F 55 26 0 nr 0 0 none improved nr

PE2195 M 62 32 0 nr 0 0 none no improved

SDR2579 M 45 41 0 0 0 0 none no no

EE2314 F 50 19 0 0 0 2 none no improved

CF2689 M 39 14 0 nr 0 0 none improved nr

MS2784 F 27 21 0 nr 0 0 none improved nr

PS2762 M 31 21 0 nr 0 0 none no nr

DL2390 F 25 41 0 0 0 0 none no improved

SN2835 F 27 30 0 0 0 0 none improved no

LM2862 F 26 16 0 1 0 0 none improved no

RM2452 M 44 37 1 1 0 0 none improved nr

MF2665 M 44 45 1 1 0 0 none no no

BF2812 M 32 28 0 nr 0 2 none improved nr

JF2887 M 41 16 0 1 0 0 none no improved

MG2890 M 38 36 0 0 0 1 none no no

EG2701 M 26 34 0 0 0 0 none no no

LG2367 F 26 42 1 1 0 0 none no nr

AG2558 F 46 46 0 1 0 0 none no no

MG2793 F 34 32 0 0 0 0 none improved no

MG2709 F 25 20 0 1 0 5 none improved improved

AG2338 M 40 28 0 0 0 0 none no nr

MH2361 M 43 28 0 0 0 0 none no improved

SM2954 M 27 21 0 0 0 0 none no no

GL2952 F 37 14 1 0 0 0 none no no

¹ Measurement were taken 24 hours after medication was first taken.

[0051] Many modifications and variations are possible and would be apparent to a person skilled in the art in light of the above teachings. It is therefore to be understood that the invention can be practiced otherwise than as specifically described herein and still will be within the spirit and scope of the appended claims.

15

Claims (48)

What is claimed is:

1. A mouthwash composition formulated for the treatment or prevention of bacterial and fungal infection in the oral cavity, the mouthwash composition comprising an effective amount of metronidazole and nystatin, together with an orally-acceptable carrier.

2. A mouthwash composition formulated for the treatment or prevention of bacterial and fungal infection in the oral cavity, the mouthwash composition comprising an effective amount of metronidazole and nystatin, together with an orally-acceptable carrier, with the provision that metronidazole is not present at a concentration of 50 mg/ml when nystatin is present at a concentration of 100,000 I.U./ml and nystatin is not present at a concentration of 100,0001.U./ml when metronidazole is present at a concentration of 50 mg/ml.

3. A mouthwash composition according to claim 1 or 2, wherein metronidazole is present at a concentration of about 5 to about 200 mg per ml and wherein nystatin is present at a concentration of about 20,000 to about 600,000 LU. per ml.

4. A mouthwash composition according to claim 1 or 2, wherein the composition is an aqueous suspension.

5. A mouthwash composition according to claim 3, wherein the composition is an aqueous suspension.

6. A mouthwash composition according to claim 1 or 2, formulated for the treatment or prevention of halitosis.

7. A mouthwash composition according to claim 3, formulated for the treatment or prevention of halitosis.

16

8. A mouthwash composition according to claim 1 or 2, formulated for the treatment or prevention of a periodontal disease.

9. A mouthwash composition according to claim 3, formulated for the treatment or prevention of a periodontal disease.

10. A mouthwash composition according to claim 1 or 2, formulated for the treatment or prevention of gingival inflammation or bleeding.

11. A mouthwash composition according to claim 3, formulated for the treatment or prevention of gingival inflammation or bleeding.

12. „ A mouthwash composition according to claim 1 or 2, wherein the bacterial infection is caused by a bacterial pathogen selected from the group consisting of Bacteroides sp, Fusobacterium sp, Spirochetes, Clostridium sp, Peptococcus sp and Peptostreptococcus sp.

13. A mouthwash composition according to claim 3, wherein the bacterial infection is caused by a bacterial pathogen selected from the group consisting of Bacteroides sp, Fusobacterium sp, Spirochetes, Clostridium sp, Peptococcus sp and Peptostreptococcus sp.

14. A mouthwash composition according to claim 1 or 2, wherein the fungal infection is caused by a Candida fungal pathogen.

15. A mouthwash composition according to claim 3, wherein the fungal infection is caused by a Candida fungal pathogen.

16. A composition according to claim 1 or 2, further comprising a corticosteroid.

17. A composition according to claim 3, further comprising corticosteroid.

17

18. A composition according to claim 16, wherein the corticosteroid is hydrocortisone.

19. A composition according to claim 17, wherein the corticosteroid is hydrocortisone.

20. A composition according to claim 1 or 2, further comprising a pain relief agent.

21. A composition according to claim 3, further comprising a pain relief agent.

22. A composition according to claim 16, further comprising a pain relief agent.

23. A composition according to claim 17, further comprising a pain relief agent.

24. A composition according to claim 20, wherein said pain relief agent is lidocaine.

25. A composition according to claim 21, wherein said pain relief agent is lidocaine.

26. A composition according to claim 22, wherein said pain relief agent is lidocaine.

27. A composition according to claim 23, wherein said pain relief agent is lidocaine.

28. A method for the treatment or prevention of bacterial and fungal infection in the oral cavity, the method comprising the step of rinsing an oral cavity with a composition comprising an effective amount of metronidazole and nystatin, together

18 with an orally-acceptable carrier.

29. A method for the treatment or prevention of bacterial and fungal infection in the oral cavity, the method comprising the step of rinsing an oral cavity with a composition comprising an effective amount of metronidazole and nystatin, together with an orally-acceptable carrier, with the provision that metronidazole is not present at a concentration of 50 mg/ml when nystatin is present at a concentration of 100,000 I.U./ml and nystatin is not present at a concentration of 100,000 I.U./ml when metronidazole is present at a concentration of 50 mg/ml.

30. The method of claim 28 or 29, wherein metronidazole is present at a concentration of about 5 to about 200 mg per ml and wherein nystatin is present at a concentration of about 20,000 to about 600,000 LU. per ml.

31. A method according to claim 28, 29 or 30, wherein the composition is applied to treat or prevent halitosis.

32. A method according to claim 28, 29 or 30, wherein the composition is applied to treat or prevent a periodontal disease.

33. A method according to claim 28, 29 or 30, wherein the composition is applied to treat or prevent gingival inflammation or bleeding.

34. A method according to claim 28, 29 or 30, wherein the bacterial infection is caused by a bacterial pathogen selected from the group consisting of Bacteroides sp, Fusobacterium sp, Clostridium sp, Spirochetes, Peptococcus sp and Peptostreptococcus sp.

35. A method according to claim 28, 29 or 30, wherein the fungal infection is caused by a Candida fungal pathogen.

36. Use of an effective amount of metronidazole and nystatin for the manufacture

19 of a product for the treatment or prevention of bacterial and fungal infection in the oral cavity.

37. Use of an effective amount of metronidazole and nystatin for the manufacture of a product for the treatment or prevention of bacterial and fungal infection in the oral cavity, with the provision that metronidazole is not present at a concentration of 50 mg/ml when nystatin is present at a concentration of 100,000 I.U./ml and nystatin is not present at a concentration of 100,000 I.U./ml when metronidazole is present at a concentration of 50 mg/ml.

38. A use according to claim 36 or 37, wherein metronidazole is present at a concentration of about 5 to about 200 mg per ml and wherein nystatin is present at a concentration of about 20,000 to about 600,000 LU. per ml.

39. A use according to claim 36, 37 or 38, wherein the product is an aqueous suspension.

40. A use according to claim 36, 37 or 38, wherein the product is formulated for the treatment or prevention of halitosis.

41. A use according to claim 36, 37 or 38, wherein the product is formulated for the treatment or prevention of a periodontal disease.

42. A use according to claim 36, 37 or 38, wherein the product is formulated for the treatment or prevention of gingival inflammation or bleeding.

43. A use according to claim 36, 37 or 38, wherein the bacterial infection is caused by a bacterial pathogen selected from the group consisting of Bacteroides sp, Fusobacterium sp, Spirochetes, Clostridium sp, Peptococcus sp and Peptostreptococcus sp.

44. A use according to claim 36, 37 or 38, wherein the fungal infection is caused by

20 a Candida fungal pathogen.

45. A use according to claim 36, 37 or 38, wherein the product further comprises a corticosteroid.

46. A use according to claim 45, wherein the corticosteroid is hydrocortisone.

47. A use according to claim 36, 37 or 38, wherein the product further comprises a pain relief agent.

48. A use according to claim 47, wherein said pain relief agent is lidocaine.

21